A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

Trial Profile

A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Aldesleukin (Primary) ; PNK 007 (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation; Celularity
  • Most Recent Events

    • 27 Feb 2018 Planned number of patients changed from 40 to 46.
    • 27 Feb 2018 Planned End Date changed from 30 Nov 2018 to 30 Apr 2020.
    • 27 Feb 2018 Planned primary completion date changed from 30 Nov 2018 to 30 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top